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Abstract
The COVID-19 pandemic has created new barriers for people suffering from mental illness and
substance use disorders. From its expected major impact on mental health, social distance
measures imposed worldwide are themselves risk factors for increased mental health problems,
including opioid abuse. Since drug treatment for opioid use disorders is highly regulated by
health authorities, people with opioid use disorders could experience difficulty accessing
treatment, which should be considered an essential treatment during the COVID-19 pandemic.
The accelerated transition away from in person appointments and group therapy because of
social distancing calls for health systems and community collaborations and adjustments to
clinical practice. This includes emphasizing mental health training for healthcare providers and
frequent communication between providers and patients, increasing the flexibility of take home
medications and access to overdose reversing medications, and leveraging technology through
the use of telehealth and virtual support groups to optimize safety of medication treatment and
increased support during this time. This paper explores mental health and substance use in the
context of the COVID-19 pandemic, the challenges to accessing mental health and substance use
services, and gives recommendations towards planning for the health needs of opioid abusers
during future times of crises.

Keywords: COVID-19, opioid use, substance abuse disorders, mental health, telehealth, drug
treatment, pandemic, social distancing, crisis preparedness, crisis health needs
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Introduction
Social distancing represents a critical public health strategy to limit the increase in cases
and deaths from COVID-19 and helps to prevent the overwhelm of healthcare systems during
disease outbreaks. Social distancing for COVID-19 includes the need to shelter in place to avoid
exposure, quarantine from others due to possible exposure, or having to go into isolation due to a
confirmed diagnosis for 14 days or more. One group that may be especially vulnerable in
quarantine and isolation is those who suffer from opioid addictions. When a crisis occurs, public
health and medical responders must be ready to care for users of opioids who are going through
withdrawal, patients who are in recovery, and patients who require opioids for pain management.
People who are dependent on opioids encounter significant health inequities, including excess
mortality connected to drug overdoses, suicides, traumatic deaths, and infectious
diseases(Herdener et al, 2017). For those in treatment for substance abuse disorders and those
who administer them, COVID-19 produces new barriers that make accessing these crucial
services more challenging.
The COVID-19 pandemic has isolated many people, restricted them from their friends,
family, and support. Fear and anxiety about COVID-19 can result in people feeling more anxious
and stressed. Feelings of loneliness that are heightened during social distancing can result in poor
mental health. From its anticipated impact on mental health, social distance requirements
enforced worldwide are themselves risk factors for multiple mental health issues including
substance abuse. Prior to the COVID-19 pandemic, nearly one in five U.S. adults reported
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having a mental illness in the past year, and over 11 million had a serious mental illness, which
frequently results in functional impairment and limits life activities(Mota, 2020).
Not all individuals who suffer from mental illness have substance abuse problems, but
most substance abusers do suffer from mental illness. Substance use disorders and mental health
problems often occur simultaneously. This is because they share many fundamental causes,
including changes in brain composition, genetic vulnerabilities, and early exposure to stress or
trauma. Mental health issues can sometimes lead to drug use, as some people with mental health
problems may misuse these substances as a way of self-medicating. During times of uncertainty
and uneasiness, it is possible that mental illness and substance use disorders among patients with
these illnesses could worsen. Planning for the crisis health needs of opioid abusers by forming
health system and community collaborations, as well as making existing mental health and
substance abuse treatment programs and medications more accessible is critical to diminish
disruptions from future crises.

Background

Planning for Emergencies
Substance abuse treatments have not been given much consideration from the
preparedness community yet researchers have identified that substance abuse treatment programs
have experienced large disruptions during past times of crises. Past times of crisis in the United
States, like Hurricane Katrina and the 9/11 attacks, have been followed by increases in the
prevalence of mental illness and substance abuse(Galea, 2007). Hurricane Katrina caused the
immediate closure of all substance abuse treatment services in New Orleans(Torielle et al, 2007).
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New York City opioid treatment programs reported substantial difficulties verifying doses and
medication take-home privileges for patients who were unable to access their usual programs
after the 9/11 attacks(Frank et al, 2003). After Hurricane Sandy in 2012, interviews of 300 New
York City residents who injected drugs were conducted to interpret how that natural disaster
influenced their medical treatment. This study found that only 30.1% of those on methadone or
buprenorphine were able to obtain enough take-home doses to last them until their normal
treatment resumed(Pouget et al, 2015).
Public health and health care professionals need to incorporate the management of
problems related to opioid use as part of their overall preparedness, response, and recovery plans.
Individuals with preexisting disorders are particularly at risk of adverse outcomes during and
after times of crises. Without advance planning from health care professionals and policy
makers, these individuals may not benefit from necessary mental health services and treatments
during and after future crises(Rabins, 2011). Through the development of community and health
system collaborations, plans to address access to treatment and medications can be formed prior
to another crisis, like COVID-19, occurring.

Health Impacts of COVID-19 on Opioid Abusers
Opioid abusers are particularly vulnerable during the COVID-19 pandemic. They may be
alone, recently unemployed, overworked if they are considered essential employees, and
overburdened with stress. If they are in an addiction treatment program, they may rely on group
sessions for support. COVID-19 and opioid addiction can impact and worsen each other. Prior to
COVID-19, the mortality ratio, compared to the general population, was about 15 times greater
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for opioid use disorders(Chesney et al., 2014). Deaths due to drug overdose have increased more
than threefold over the past 20 years, from 6.1 deaths per 100,000 people in 1999 to 20.7 deaths
per 100,000 people in 2018(WHO, 2018). Drug deaths have risen an average of 13 percent so far
in 2020 over 2019, according to mortality data from local and state governments collected by
The New York Times, covering 40 percent of the U.S. population(Katz, 2020).

FIGURE 1 shows the increase in drug related deaths from 2019 through the beginning of
2020

https://www.nytimes.com/interactive/2020/07/15/upshot/drug-overdose-deaths.html

The opioid abuse epidemic and the COVID-19 pandemic are now overlapping, making
them additively deadly. Substance use disorders are associated with a considerably large disease

8
burden and the highest mortality among all mental and behavioral disorders(WHO, 2017).
People who suffer from the disease of addiction are more vulnerable to both contracting
coronavirus and having more severe symptoms when they do get it. There is an increased burden
of respiratory diseases in individuals who use illicit opioids, making this group more vulnerable
to the pandemic threat, as there is an elevated risk of overdose, since these substances can
depress breathing(Mota, 2020). Chronic respiratory disease is already known to increase the risk
of overdose among individuals taking opioids, and thus the decrease in lung capacity from
COVID-19 could similarly endanger this population(NIDA, 2020). Since opioids operate in the
brainstem to relax breathing, their use could result in a life-threatening or fatal overdose and
could also lead to a detrimental decrease in oxygen in the blood, which can be especially harmful
for the brain(NIDA, 2020). Opioid use could also result in a weakened immune system,
increasing an individual's susceptibility to pneumonia(Sarkar, 2015).

Socioeconomic Factors Associated with Opioid Abusers
Opioid abusers and those who access substance abuse treatment services may be at an
increased risk of losing access to services and of contracting COVID-19. Individuals who
contend with addiction are more likely to smoke and have lung or cardiovascular disease, be low
income, underinsured or uninsured, or have experienced severe health and socioeconomic
problems from drug addiction. Additionally, those with a substance use disorder are at an
increased likelihood of experiencing homelessness or incarceration than those in the general
population, and these circumstances offer additional challenges when it comes to transmission of
coronavirus. Homelessness or incarceration can place individuals in congregate settings where
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they are in close proximity with others who may also be at a greater risk of contracting
coronavirus(NIDA, 2020). All of these socioeconomic factors increase the susceptibility of this
population being exposed to and becoming infected with the virus.

Stigma Surrounding Substance Use Disorders
Stigma is defined as a set of negative beliefs that a group or society holds about a topic or
group of people(Ahmedani, 2011). Opioid abusers who encounter stigma related to their drug
use are less likely to pursue treatment resulting in economic, social, and medical costs. The
stigmatization of individuals with opioid abuse disorders may be even more problematic during
times of crisis. Along with their increased risk through homelessness and drug use itself, the
genuine fear surrounding contracting COVID-19 could result in bystanders and even first
responders being hesitant to help and give naloxone to those who have overdosed. There is also a
possibility that hospitals will overlook individuals with apparent drug problems when making
tough decisions about how to direct lifesaving personnel and resources(NIDA, 2020). The stigma
applied to addiction and the illegality of drug use mean that many adverse outcomes and
treatment decisions are possible.
Because of stigma, funds are less likely to be allocated to opioid abusers particularly
when there are so many other demands. The stigma surrounding opioid abuse could result in
legal, policy, funding, and community barriers to creating a crisis fund dedicated to the health
needs of those with substance abuse disorders. As policymakers continue to discuss further
actions to alleviate the burdens of the COVID-19 pandemic, plans for the health needs of opioid
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abusers during the recovery and for future crises, as well as how to combat the stigma
surrounding this population need to be addressed.

Disruptions in Healthcare Services
For someone struggling with addiction, many services and treatments available to them
have been disrupted by the COVID-19 pandemic. Treatment centers have had to restrict the
number of patients they can see in person(Mota, 2020). People have been advised to stay home
which combats the need of those struggling with addiction to go to clinics to receive
medications. In response to this, our federal government has relaxed regulations so that clinics
are able to give 14-day or even 28-day supplies in some cases to patients that have a history of
complying with program instructions and can be expected to take their prescribed medication as
instructed, so that they do not have to wait in line and can adhere to social distancing for
safety(Grinspoon, 2020).
Similarly, due to the COVID-19 pandemic, some restrictions on buprenorphine
prescribing have also been relaxed and some telephone prescribing has been permitted, but this
action assumes that there are doctors available that are certified to prescribe this medication, and
that the pharmacies and doctors’ offices are functioning at regular capacity. During the
COVID-19 pandemic, many medical offices are functioning with fewer staff or adjusting to
working remotely which results in longer wait times and slower responses from doctors.
Additionally, clean needle exchanges have been affected and many rehabilitation facilities have
limited new admissions or cancelled programs due to fear of spreading coronavirus in a
communal living setting(Grinspoon, 2020). The disruption of steady-state systems necessary for
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medical care, such as medical facilities and treatment programs, could increase the likelihood of
opioid abusers searching for alternatives to prescribed medications that may be more easily
available to them, like heroin and illegally made fentanyl.
Disruptions in service are a reality during times of crises. For those with behavioral
health and opioid abuse disorder, dealing with an infectious disease outbreak and adjustments in
access to medications and treatments can lead to additional crises(Pyle, 2020). Stress is a
prominent risk factor related to the maintenance of opioid abuse. Times of ambiguity could result
in an increase in misuse and relapse of substance use disorders(Clay, 2020). Troubling times
could also result in people suddenly needing to manage their habits and addiction related
symptoms when other support systems may be depleted or absent. Public health, healthcare, and
emergency management planners and responders should plan for how to decrease the adverse
effects of addiction withdrawal. Housing instability as well as reduced access to health care and
recovery support services introduce added challenges for opioid abusers(Mota, 2020). As efforts
to address the opioid epidemic unfold, federal, state, local, and community organizations must
collaborate in planning for and responding to crises.

Disruptions in Mental Health Services
Limited access to mental health care and substance use treatment programs is partially
due to the current shortage of mental healthcare providers, which will likely be worsened by the
COVID-19 pandemic. The use of telemedicine among behavioral health professionals is a
promising approach to lessen the need for mental health providers and increase access to mental
health and substance use disorder treatment throughout the United States. While some mental
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health professionals have expanded by using telehealth due to social distancing requirements,
some providers may experience challenges. Challenges related to the delayed implementation of
telehealth by the mental healthcare field are largely due to insurance billing restrictions and state
licensing laws that prohibit providers from helping patients across state lines(Panchal et al,
2020).
In recent years, only the Department of Defense and the Veterans’ Affairs Healthcare
System, both federal systems without such restrictions, have been able to provide an ample
amount of mental health care support through telehealth. Due to the COVID-19 pandemic,
long-established regulations in the United States have been temporarily waived for patients,
particularly vulnerable populations, and health professionals to experience the advantages of
telehealth(Egede et al, 2020). This could benefit opioid abusers who are sheltering in place and
need access to mental health services.
Going forward, it is critical that the emergency deregulation laws that have been
authorized during the COVID-19 crisis are made permanent in order to support telehealth use in
mental healthcare services. However, financial barriers to implementation, such as lack of
reimbursement, cost of implementation, and cost of maintenance could be possible reasons why
some providers could deter from using telemedicine. Other barriers could include a lack of
organizational and political leadership, workforce shortages, confidentiality, educational and
training barriers, and compliance barriers such as licensure regulations(Pyle, 2020).
Funds from the recently-passed Coronavirus Aid, Relief, and Economic Security Act
(CARES Act) were allocated to combat the probable heightened need for mental health and
substance use services. The CARES Act contains a $425 million allotment to be used by the
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Substance Abuse and Mental Health Services Administration (SAMHSA), along with multiple
provisions proposed for expanding the availability and coverage of telemedicine for those
covered by Medicare, private insurance, and other federally-funded programs(Panchal et al,
2020).
Concerns regarding the release of identifying patient information have been generated by
the CARES Act. Patients usually consent to release their treatment information when they are
admitted to a program. This is mandatory for insurance to cover the treatment. But under the
CARES Act, reasons for why the information could be used in the future are not evident. The
three potential uses for identifying patient information that the Cares Act authorizes are:
treatment, payment, and healthcare operations. The last category is broad, and could lead to the
release of this information to all kinds of entities and people outside the limits of what a typical
patient would want. The negative implications of this could be severe and result in job loss,
could be concerning in custody battles, and could result in insurance companies using substance
abuse history to deny future payments(NatLaw, 2020). The goal of this allotment from the
CARES Act is to expand services, ensuring that patient information is confidential and receives
the same protections from existing privacy regulations is important. Future data is required to
measure the growing effect on mental health and substance use that the COVID-19 pandemic has
had, as well as research regarding the ethical concerns surrounding confidentiality and the
CARES Act.
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Recommendations

Health Systems and Community Collaborations and Partnerships
Individuals with preexisting disorders and newly emergent psychological symptoms are
particularly vulnerable to adverse outcomes during and after emergencies due to added stress and
isolation. Without advance planning, these individuals may not benefit from necessary mental
health services and treatments during and after crises(Rabins, 2011). Collaboration among health
system leaders from hospital and community mental health systems are needed to ensure the
continuity of care for individuals experiencing mental health crises(Choi et al, 2020). There is
opportunity for health system planning, resource mobilization, and new interventions to address
obstacles faced by mental health providers and patients due to the COVID-19 outbreak.
Through these collaborations, support mechanisms for combating outbreak-related stress
can be developed and implemented. This could include extended hotline hours and additional
personnel to decrease hotline wait times, providing stress relieving and coping exercises/videos,
and help with applying for benefit programs. Innovative models of mental health care need to be
carried out so those who need support can access professional treatment. Telehealth, increased
provider mental health training, virtual peer support, and virtual substance use support groups
could help to ensure that mental health needs are being met(Choi et al, 2020). Using these virtual
options more routinely will be beneficial in the long run, as they will be less likely to be
disrupted during future crises and may also attract individuals who have deterred from in person
substance abuse services in the past due to fear of stigma.
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FIGURE 2 displays the calls and texts to SAMHSA’s Disaster Distress Helpline after
COVID-19 was declared a national emergency

Increase Flexibility and Guidance in Dispensing Extended Take-home Medications and
Supplies
Greater flexibility in dispensing take-home medication, such as supplying extended doses
of methadone to patients due to social distancing restrictions, combined with isolated
consumption, could increase vulnerability to relapse and overdose, being that there may not be
anyone around who can administer naloxone to reverse an overdose(Mota, 2020). New policies
have been implemented due to COVID-19 at the federal level by SAMHSA and the Drug
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Enforcement Administration (DEA) that allow healthcare providers the option of supplying
patients with opioid use disorder extended take-home doses of buprenorphine and methadone.
In combination with these medications, individuals battling addiction need to be
supported through online meetings in place of their normal in person meetings, so that they are
not alone and are still receiving guidance from their providers. The rapid move to dispense larger
amounts of medications assumes that all patients receiving these larger quantities have proficient
substance management. Thus, a substantial portion of these patients may face a responsibility of
medication management for which they may not be prepared. To supply increased amounts of
take-home medications as a substitute for daily in person appointments without continuing
behavioral treatment mistakenly views this type of treatment as merely medication
therapy(Leppla et al, 2020).
Remote management calls for providers to leverage telehealth in order to maintain
frequent contact with patients. An additional opportunity for providers supplying increased
amounts of take-home medications to patients who may not be ready to handle the access to
larger doses is to leverage technology, such as “smart” pill bottles/lock boxes that dispense doses
on a remotely set timescale and also alert providers if incorrect doses have been taken. These
technologies are costly, experimental, and may not be widely available in mass
production(Leppla et al, 2020). Making these options more affordable to produce and
manufacture could be beneficial, not just during times of crises, but for use with all prescription
drugs that are known to be addictive. It is essential that opioid abusers are receiving the
medications they need to recover, that they have access to clean needles if they are still using, as
well as adequate medical care.
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After Hurricane Katrina, SAMHSA issued guidance for opioid treatment programs
receiving individuals displaced by Hurricane Katrina. SAMHSA's guidance consisted of
procedures for authenticating identification, corroborating proof of treatment, and determining
dosage information. The guidance stated that if unable to follow these procedures, providers
should use “good medical judgement.” The guidance emphasized the need to abide by federal
regulations, particularly concerning provision of take-home amounts and records of
treatment(Curie, 2005). Learning from this event and expanding on this idea by implementing
provider training so that they know what constitutes as “good medical judgement,” as well as
instilling confidence in their prescribing abilities could be a beneficial way to adopt this guidance
during future crises.

Expand Access to Medication-assisted Treatment (MAT)
The CDC defines Medication-assisted Treatment as a comprehensive way to address the
needs of individuals [with opioid use disorder] that combines the use of medication (methadone,
buprenorphine, or naltrexone) with counseling and behavioral therapies. Opioid abuse often
leads to addiction, which can result in changes in the brain’s structure and functions. MAT
counteracts and fights these changes by inhibiting certain receptors in the brain. This treatment
plays a significant role in controlling withdrawal symptoms as patients work towards managing
their recovery(CDC, 2018). Buprenorphine is a medication with complicated dosing, which is
why it requires additional knowledge and a waiver requirement, showing that the provider has
met the additional educational requirement to prescribe this medication. Buprenorphine is highly
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regulated as it can cause respiratory distress and death when taken in incorrect doses or when
combined with other substances(Bagalman, 2015).
In order to care for patients with buprenorphine outside of traditional federally certified
opioid treatment programs, health care providers must apply for and obtain a waiver from the
DEA. Providers with a waiver can treat 30 patients in the first year and 100 patients after having
a waiver for one year; certain qualified physicians can request a waiver to treat up to 275 patients
after having a 100 patient waiver for one year (Bagalman, 2015). Nationwide, there is a deficit of
providers who provide MAT, specifically waivered providers that can prescribe buprenorphine.
In 2016, only 52.5% of counties in the United States had at least one waivered provider and only
39.9% of rural counties had at least one waivered provider in 2016(Andrilla et al, 2017).
Quantifying these shortages can be problematic because some providers who acquire waivers
may not help the maximum number of patients permitted, or treat any patients at all. It can be
challenging to comprehend why some providers are not obtaining waivers.
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TABLE 1 displays perceived barriers to providers obtaining MAT waivers and policy
recommendations to address these barriers

Waiving the limitations on the number of patients a provider can treat would be
beneficial during times of crises and result in more opioid abusers having access to this
treatment. Making these waivers more easily obtainable as well as waiving the patient limit per
provider during the pandemic could be beneficial and give more health professionals the
opportunity to help more patients. Health care professionals would need to plan for the best way
to dispense the necessary medications to patients who are in quarantine, such as using delivery
services and providing patients with set dosing schedules, as well as utilizing telehealth and
video appointment methods to set up counseling and behavioral therapy sessions. In the future,
eliminating the waiver process for physicians altogether, when complemented by policies to
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increase provider education during graduate school, would be beneficial. Buprenorphine
prescriber training can be more effective if incorporated into graduate school medical education,
similar to training often integrated for other prescriptions with complicated dosing, like
warfarin(Haffajee et al, 2018).

Increase Access to Overdose Reversing Medications
Overdose reversing medications for opioid use disorders can be immediately effective
and life-saving. They are highly regulated by health authorities which could result in individuals
with opioid use disorders facing even greater challenges to obtaining opioid agonist treatment
during times of crises(WHO, 2020). Naloxone and the generic version Narcan are prescription
drugs that can reverse opioid overdoses. State laws and regulations restrict access to both. There
have been concerns that if naloxone was viewed as a safety net, it would encourage people to use
more opioids. Several studies have demonstrated that this is not the case and increased naloxone
access has shown no increase in behaviors associated with opioid ingestion(Davis et al, 2015).
As of 2020, all fifty states and the District of Columbia have adjusted their regulations to
improve access to naloxone, but there are other legal and regulatory changes that can further
increase access and availability(CDC, 2018).
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TABLE 2 compares the different prescription models for Naloxone in the United States

Information obtained from: State Naloxone Access Rules and Resources. (n.d.). Retrieved from
https://www.safeproject.us/naloxone-awareness-project/state-rules/

At the state level, those that have not passed regulation that expand layperson access to
naloxone should prioritize doing so to aid in counteracting the adverse effects of the COVID-19
pandemic on opioid abusers. This will result in more individuals having access to the overdose
reversing medications that could save their own or their loved one’s life. Those that have
implemented layperson access should assess whether or not the provisions of their regulations
are achieving the desired outcome. In many cases, this could call for not only allowing naloxone
to be accessed in pharmacies without a patient-specific prescription, but also permitting the
distribution of it at drug treatment programs and health clinics(Davis, 2015).
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Ensuring easy accessibility to take-home naloxone for patients is crucial for reducing
overdose risks and providing deliveries of naloxone to the homes of individuals with positive
COVID-19 diagnoses is necessary to comply with home isolation recommendations. A
meta-analysis of 12 examinations of naloxone access programs found that the programs were
associated with successful training of both people at high risk of an overdose and their friends
and family when it came to acknowledging an opioid overdose and appropriately administering
naloxone, and no increase in drug use or high-risk behavior (Haegerich, Paulozzi, Manns, &
Jones, 2014).
Even without the ability to authorize third party prescriptions, research shows that
educating family or friends about the signs of overdose and use of naloxone helps to prevent
overdoses(CDC, 2018). Given the constraints of seeking providers who prescribe naloxone and
accessing distribution programs, relabeling naloxone as an over-the-counter drug in the states
that have not yet adopted this method should be considered. Naloxone has been available
over-the-counter in Italy since the 1980s without any reported negative consequences(Burris et
al, 2001). Developing a delivery system of Naloxone and Narcan during times of crises, in which
those unable to go pick up a prescription can get them delivered, would help to reduce the
amount of opioid related overdose deaths.

Implications
The total economic burden of opioid abuse alone in the United States in 2018 was
estimated at $631 billion, including the costs of healthcare, lost productivity, addiction therapy,
and criminal justice involvement(Siegel, 2019). The misuse of and the dependency on opioids
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from addicts, including prescription pain relievers, heroin, and fentanyl, are a leading cause of
overdose deaths and are a serious issue in the United States that affects public health as well as
social and economic welfare(NIDA, 2020). Pandemic-related stressors could result in an increase
in the prevalence of opioid usage. Thoughtful mental health care preparation and implementation
of substance abuse practices are vital because without advance planning, opioid abusers may not
benefit from and may not know how to access necessary mental health services and treatments
during future crises. Support mechanisms offered by health systems like extended hotline hours
and additional personnel to decrease hotline wait times, supplying stress relieving and coping
exercises and videos, and help with applying for benefit programs would help to alleviate
pandemic-related stress. These support mechanisms could help alleviate much of the stress added
by the pandemic and help to reduce the pandemics impact on individuals with mental health and
substance abuse disorders.
Although unprepared for the September 11th attacks, New York City's mental health
system was able to act quickly. Within weeks, Project Liberty, a recovery program funded by the
Federal Emergency Management Agency (FEMA), was fully operational. A mental health
hotline was created called LifeNet to supply free information and counseling assistance to those
afflicted by 9/11 and its aftermath. These services helped to relieve stress and anxiety
accumulated by those most closely affected(Reissman, 2004). While this study did not directly
reference opioid abusers, it can be expected that this relief effort would have had a positive
impact on addicts who suffered from stress surrounding their treatment following the 9/11
attacks. Determining additional necessary support mechanisms could be done through a
collaboration among health system leaders from hospital and community mental health systems
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to assure that needs are met. A limitation of this could be the cost and the difficulty of planning
for something that may not happen. Using money to plan for a possible crisis means that this
money will not be allocated to other projects that may have a more urgent demand for it. As
policymakers continue to discuss further actions to alleviate the burdens on opioid abusers
following public health crises, plans for their health needs and how to combat the stigma
surrounding this population need to be addressed. The lessons learned from COVID-19
surrounding access to support services and treatments, as well as expanded medication access
will be beneficial in the response plans and preparations for future public health crises.
Implementing more innovative models of mental health care will help to ensure that
community mental health needs are addressed. Telehealth, virtual mental health counseling, and
virtual support groups help meet community needs by ensuring professional and social support
during quarantine. Extended medication supplies allow patients to have increased access to the
medications they need while complying with social distancing and quarantine recommendations.
Increased provider mental health education that aims at addressing the mental health needs of
opioid abusers and how to best address these needs is critical to help alleviate any stress and
negative thoughts that this population could develop during times of crises. By providing patients
with additional methods of healthcare access and access to support groups and by ensuring that
health providers are trained to address the mental health issues of patients and the best ways to
address these issues from a distance, an increase in mental health issues, such as stress and
heightened anxiety, could be diminished.
A limitation to expanding telehealth and virtual mental health and peer support meetings
is that participants may find these options impersonal or feel that their needs cannot be fully
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addressed virtually and opt out of them. Connection and bandwidth issues could also be an issue
during medical appointments and could result in miscommunications between patients and
healthcare providers and incorrect information being recorded in patients’ charts. Another issue
that can be seen with telehealth is whether or not and how these online platforms are compliant
with confidentiality. Virtual meetings and support groups, while helpful for some patients, may
further marginalize patients without the availability of a phone or video platform. One solution is
to supply prepaid phones or phone cards with enough minutes for appointment uses. Another
challenge related to having medical appointments virtually is that patients may lack secure or
private settings from which to have these appointments(Leppla et al, 2020).
An issue with extended take home medication could be the responsibility put on patients
to follow their medication regimen without the support that in-person counseling offers. This
could result in added stress on patients and a likelihood that they will be unable to comply with
their treatment process. Patients may fail to take medications as directed due to a lack of
guidance felt by the loss of in person appointments. The loss of in person interaction between
patients and providers needs to be supplemented by frequent telehealth appointments and
communication with providers.
By making the waivers needed to practice Medication-assisted treatment more easily
accessible and by employing telehealth methods and easier access to necessary medications,
more individuals with substance use disorder would have access to this treatment option.
Limitations of MAT, especially relevant during this pandemic, would be time it takes for
providers to get a waiver and also the anticipated barriers that providers might see like time
constraints, resistance from practice partners, lack of available mental health support for patients,
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and lack of confidence in their ability to manage substance use disorders(Andrilla et al, 2017).
These barriers highlight opportunities to encourage providers who would like to obtain MAT
waivers. Overall, more research is needed to determine how to increase the number of waivered
providers and thus increase the amount of people who can access MAT during times of crises.
Randomized controlled trials could be beneficial to analyze how implementing graduate
coursework for medical students on buprenorphine prescribing in place of receiving a waiver
could result in an increase in MAT providers in the future and allow for more access for patients
seeking this type of treatment.
Further increasing the availability of overdose reversing medications, such as naloxone
and narcan, by creating a policy that makes over the counter access to naloxone during times of
crises in all states could result in less overdose related deaths and serious hospitalizations. By
allowing over the counter access of naloxone or increased access to those who are most likely to
witness an overdose, many overdose deaths could be prevented. A delivery system for naloxone
would be especially beneficial for individuals who are in quarantine and for those in rural areas
who may not have easy access to pharmacies and other distribution sites.
As of April 2020, there had been 140 more naloxone administrations in 2020 than the
entire year of 2019 in York County, Pennsylvania(YOC, 2020). This increase could be tied to
COVID-19 related stressors that are in turn increasing the use of illicit drugs. This demonstrates
the increased need for overdose reversing medications and that large supplies of Naloxone and
Narcan should be made available and easily accessible to opioid abusers, friends and family of
abusers, and to emergency personnel during times of crises. A limitation of this would be access
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to the amount of supply needed during times of crises and the cost of naloxone, which can vary
whether or not the generic version is available, for those that do not have insurance coverage.

Conclusion
The COVID-19 pandemic is likely to have both long and short-term implications for
mental health and substance use. Knowledge of the opioid epidemic has been mainly limited to
scattered statistics that only acknowledge some aspects of the epidemic, like particular
geographic regions, limited time periods, and specific drugs. Additionally, we lack a
comprehensive examination of the substance abuse epidemic in the context of the COVID-19
pandemic that acknowledges the complex and progressing dynamics of drug abuse in the United
States during times of crises. For those in treatment for substance abuse disorders and those who
provide them, COVID-19 introduces new barriers that make accessing these necessary services
more challenging. The growing need for mental health and substance use treatment could result
in a long-term problem even as new diagnoses and fatalities due to COVID-19 subside. By
acknowledging the legal challenges and possible solutions for substance abuse and mental health
services during and after a crisis; policy makers, emergency planners, health care professionals,
and other stakeholders can cultivate strategies to ensure that this population continues to receive
necessary treatment, even in difficult circumstances.
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Appendix
MPH Foundational Competencies
Foundational Competency
Evidence-based Approaches to Public Health
1. Apply epidemiological methods to the breadth of settings
and situations in public health practice

2. Select quantitative and qualitative data collection methods
appropriate for a given public health context
3. Analyze quantitative and qualitative data using
biostatistics, informatics, computer-based programming and
software as appropriate
4. Interpret results of data analysis for public health research,
policy and practice
Public Health & Health Care Systems
5. Compare the organization, structure and function of health
care, public health and regulatory systems across national
and international settings
6. Discuss the means by which structural bias, social
inequities and racism undermine health and create
challenges to achieving health equity at organizational,
community and societal levels
Planning & Management to Promote Health
7. Assess population needs, assets and capacities that affect
communities' health

8. Apply awareness of cultural values and practices to the
design or implementation of public health policies or
programs
9. Design a population-based policy, program, project or
intervention
10. Explain basic principles and tools of budget and resource
management
11. Select methods to evaluate public health programs
Policy in Public Health

Description of how used for Capstone
Developed a thorough literature review
after analyzing data from numerous
studies, summarizing key results, and
organizing findings in order of
importance and relevance to my topic.

Described how the socioeconomic factors
of opioid abusers create challenges for
seeking treatment and create
organizational and societal bias towards
this population.
Analyzed the treatment needs of opioid
abusers and individuals with mental
illness and assessed how these treatments
and services were disrupted by the
COVID-19 pandemic.
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12. Discuss multiple dimensions of the policy-making
process, including the roles of ethics and evidence
13. Propose strategies to identify stakeholders and build
coalitions and partnerships for influencing public health
outcomes
14. Advocate for political, social and economic policies and
programs that will improve health in diverse populations

Discussed the benefits of telehealth, as
well as extensions of different treatment
methods like MAT and easier access to
Naloxone, and how these options are
beneficial not just during a crisis, but for
long-term care.

15. Evaluate policies for their impact on public health and
health equity
Leadership
16. Apply principles of leadership, governance and
management, which include creating a vision, empowering
others, fostering collaboration and guiding decision making
17. Apply negotiation and mediation skills to address
organizational or community challenges
Communication
18. Select communication strategies for different audiences
and sectors
19. Communicate audience-appropriate public health
content, both in writing and through oral presentation

Outlined, drafted and finalized a Capstone
paper including a literature review,
recommendations and implications on
opioid abuse treatment during times of
crisis. Created a slide deck based on the
Capstone paper and delivered an oral
presentation at Health Professions Day in
front of an interprofessional audience.

20. Describe the importance of cultural competence in
communicating public health content
Interprofessional Practice*
21. Perform effectively on interprofessional teams
Systems Thinking
22. Apply systems thinking tools to a public health issue
Health Policy Leadership Concentration Competencies
Competency

Description of how Capstone used
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1. Apply economic concepts to understand the effect of
changes in policies at the government, health systems, and
public health sectors
2. Synthesize economic concepts to assess equity and
efficiency in making health policy recommendations in
underserved communities
3. Formulate efficient health policy change
recommendations through the analysis of proposed health
policy initiatives that could affect health outcomes of
vulnerable populations

4. Develop recommendations to improve organizational
strategies and capacity to implement health policy
5. Analyze policy options to address environmental health
needs at the local, state, and federal levels

Evaluated the existing policies around
Medication-Assisted Treatment and how
eliminating the waiver requirement for
providers when supplemented by
additional coursework in medical school
would result in more providers being able
to perform this type of treatment, and more
opioid abusers having access to MAT.

